Literature DB >> 2885055

Complex effects of Gillichthys urotensin II on rat aortic strips.

A Gibson.   

Abstract

The aim of this study was to determine whether the fish neuropeptide, Gillichthys urotensin II (GUII), possesses significant biological activity on rat aortic strips. On intact strips, pre-contracted by noradrenaline (100 nM), low concentrations (0.1-0.5 nM) of GUII produced relaxations, while higher concentrations (1-10 nM) caused further contraction. On strips rubbed to remove endothelial cells, relaxations were absent but contractile responses to higher concentrations of GUII remained. GUII (0.02-10 nM) produced dose-related contractions of quiescent, intact aortic strips. These contractions consisted of two components, tonic and phasic, and were potentiated in rubbed strips and in the presence of the antioxidant drug hydroquinone (10 microM). Mepacrine (40 microM) and p-bromophenacyl bromide (50 microM) completely abolished contractions to GUII, but indomethacin (10 microM) and nordihydro-guaiaretic acid (10 microM) were without effect. The phasic, but not the tonic, component of the contractile response was inhibited by nitrendipine (200 nM), and was absent in bathing medium from which Ca2+ had been omitted. Addition of EGTA (2 mM) to Ca2+-free bathing medium abolished the residual tonic component. GUII-induced contractions were completely abolished by the calmodulin antagonists trifluoperazine (50 microM) and W-7 (30 microM). It is concluded that GUII, previously considered devoid of significant activity on mammalian tissues, produces potent endothelium-dependent relaxations and endothelium-independent contractions of rat aorta, and possible mechanisms underlying each response are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885055      PMCID: PMC1853480          DOI: 10.1111/j.1476-5381.1987.tb09000.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  Mechanisms of action of transmitters and other substances on smooth muscle.

Authors:  T B Bolton
Journal:  Physiol Rev       Date:  1979-07       Impact factor: 37.312

2.  Selective inhibition by mepacrine of the release of "rabbit aorta contracting substance" evoked by the administration of bradykinin.

Authors:  B B Vargaftig; N D Hai
Journal:  J Pharm Pharmacol       Date:  1972-02       Impact factor: 3.765

3.  The importance of phospholipase-A2 in prostaglandin biosynthesis.

Authors:  R J Flower; G J Blackwell
Journal:  Biochem Pharmacol       Date:  1976-02-01       Impact factor: 5.858

4.  Tension response and 45Ca release in vascular smooth muscle incubated in Ca-free solution.

Authors:  R Casteels; L Raeymaekers; H Suzuki; J Van Eldere
Journal:  Pflugers Arch       Date:  1981-12       Impact factor: 3.657

5.  Tumor promotor 12-O-tetradecanoylphorbol-13-acetate-induced insulin secretion: inhibition by phospholipase A2-and lipoxygenase-inhibitors.

Authors:  S Yamamoto; T Nakadate; T Nakaki; K Ishii; R Kato
Journal:  Biochem Biophys Res Commun       Date:  1982-03-30       Impact factor: 3.575

6.  The effects of mepacrine and p-bromophenacyl bromide on arachidonic acid release in human platelets.

Authors:  S L Hofmann; S M Prescott; P W Majerus
Journal:  Arch Biochem Biophys       Date:  1982-04-15       Impact factor: 4.013

7.  Rat isolated mesenteric artery: a sensitive preparation for the bioassay of urotensin I.

Authors:  I Muramatsu; A Miura; M Fujiwara; K Lederis
Journal:  Gen Comp Endocrinol       Date:  1981-12       Impact factor: 2.822

8.  Anti-inflammatory and platelet anti-aggregant activity of phospholipase-A2 inhibitors.

Authors:  E Vallee; J Gougat; J Navarro; J F Delahayes
Journal:  J Pharm Pharmacol       Date:  1979-09       Impact factor: 3.765

9.  Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.

Authors:  D Pearson; J E Shively; B R Clark; I I Geschwind; M Barkley; R S Nishioka; H A Bern
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

10.  Cardiovascular effects of urotensin II in anesthetized and pithed rats.

Authors:  A Gibson; P Wallace; H A Bern
Journal:  Gen Comp Endocrinol       Date:  1986-12       Impact factor: 2.822

View more
  21 in total

1.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

3.  Enhancement of vascular smooth muscle cell migration by urotensin II.

Authors:  Satoshi Matsusaka; Ichiro Wakabayashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

4.  Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; A P Davenport; T Bennett
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.

Authors:  M R MacLean; D Alexander; A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; I Morecroft; K Polland
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 6.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 7.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

8.  Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.

Authors:  F E Bottrill; S A Douglas; C R Hiley; R White
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

9.  Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Authors:  Raffaella Vergura; Valeria Camarda; Anna Rizzi; Martina Spagnol; Remo Guerrini; Girolamo Calo'; Severo Salvadori; Domenico Regoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

10.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.